

Comparing infectivity and virulence of emerging SARS

EBioMedicine

68, 103403

DOI: [10.1016/j.ebiom.2021.103403](https://doi.org/10.1016/j.ebiom.2021.103403)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Passive Immunity Should and Will Work for COVID-19 for Some Patients. <i>Clinical Hematology International</i> , 2021, 3, 47.	1.7	4
5	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	12.8	45
7	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021, 93, 6551-6556.	5.0	79
9	Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. <i>Journal of Infectious Diseases</i> , 2021, 224, 749-753.	4.0	95
10	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	27.8	220
13	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	12.4	32
14	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	2.9	24
15	Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters. <i>Communications Biology</i> , 2021, 4, 1102.	4.4	20
16	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	12.6	262
17	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	10.3	24
18	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	12.4	41
20	Clinical Characteristics and Risk Factors for COVID-19 Infection and Disease Severity: A Nationwide Observational Study in Estonia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
22	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. <i>EBioMedicine</i> , 2021, 73, 103637.	6.1	19
23	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. <i>EBioMedicine</i> , 2021, 73, 103675.	6.1	26
26	Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations. <i>JCI Insight</i> , 2021, 6, .	5.0	21
27	Animal models for SARS-CoV-2 infection and pathology. <i>MedComm</i> , 2021, 2, 548-568.	7.2	19
29	Hamster models of COVID-19 pneumonia reviewed: How human can they be?. <i>Veterinary Pathology</i> , 2022, 59, 528-545.	1.7	49
30	Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model. <i>Journal of Infection and Public Health</i> , 2022, 15, 164-171.	4.1	7

#	ARTICLE	IF	CITATIONS
33	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	12.6	108
34	Advances and gaps in SARS-CoV-2 infection models. <i>PLoS Pathogens</i> , 2022, 18, e1010161.	4.7	61
35	The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. <i>Antiviral Research</i> , 2022, 198, 105253.	4.1	104
36	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1009914.	4.7	26
37	Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. <i>Molecules</i> , 2022, 27, 1052.	3.8	4
38	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. <i>Journal of the International AIDS Society</i> , 2022, 25, e25882.	3.0	2
39	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	27.8	79
42	An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission. <i>Npj Vaccines</i> , 2022, 7, 24.	6.0	18
43	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	30.7	281
44	The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model. <i>Communications Biology</i> , 2022, 5, 225.	4.4	10
45	MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters. <i>Frontiers in Immunology</i> , 2022, 13, 845969.	4.8	16
46	Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. <i>Microorganisms</i> , 2022, 10, 633.	3.6	3
48	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	2.8	9
49	SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic. <i>Chemical Biology and Drug Design</i> , 2022, 99, 769-788.	3.2	37
50	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	4.8	10
51	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. <i>EBioMedicine</i> , 2022, 79, 103997.	6.1	29
52	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	3.3	19
53	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 719.	12.8	86

#	ARTICLE	IF	CITATIONS
54	Ecological superâ€špreaders drive hostâ€™range oscillations: Omicron and risk space for emerging infectious disease. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	3.0	7
55	Use of wastewater surveillance for early detection of Alpha and Epsilon SARS-CoV-2 variants of concern and estimation of overall COVID-19 infection burden. <i>Science of the Total Environment</i> , 2022, 835, 155410.	8.0	34
56	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	2.7	3
57	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. <i>Viruses</i> , 2022, 14, 951.	3.3	6
58	SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model. <i>Vector-Borne and Zoonotic Diseases</i> , 2022, 22, 289-296.	1.5	2
60	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	24
61	Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia. <i>PLoS ONE</i> , 2022, 17, e0270192.	2.5	23
62	Animal models for COVID-19: advances, gaps and perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40
63	Temporal changes in the accessory protein mutations of SARSâ€™CoVâ€™2 variants and their predicted structural and functional effects. <i>Journal of Medical Virology</i> , 2022, 94, 5189-5200.	5.0	6
64	SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study. <i>Viruses</i> , 2022, 14, 1529.	3.3	4
65	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. <i>Science</i> , 2022, 377, 735-742.	12.6	85
66	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>IScience</i> , 2022, 25, 104705.	4.1	8
67	Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. <i>Microorganisms</i> , 2022, 10, 1639.	3.6	5
68	A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	3.4	5
70	SARSâ€™CoVâ€™2 does not infect pigs, but this has to be verified regularly. <i>Xenotransplantation</i> , 2022, 29, .	2.8	3
71	Evolution and consequences of individual responses during the COVID-19 outbreak. <i>PLoS ONE</i> , 2022, 17, e0273964.	2.5	2
72	Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters. <i>Virologica Sinica</i> , 2022, 37, 796-803.	3.0	4
73	Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13328-13342.	6.4	13

#	ARTICLE	IF	CITATIONS
75	Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. <i>EBioMedicine</i> , 2022, 83, 104240.	6.1	5
76	SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1 α translocation in an animal model COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	7
78	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	12.8	11
79	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. <i>PLoS Biology</i> , 2022, 20, e3001871.	5.6	11
81	Infectious droplet exposure is an inefficient route for SARS-CoV-2 infection in the ferret model. <i>Journal of General Virology</i> , 2022, 103, .	2.9	5
82	Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	9
83	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. <i>Journal of Virology</i> , 0, , .	3.4	4
85	Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?. <i>Bioelectronic Medicine</i> , 2023, 9, .	2.3	5
86	EXPERIMENTAL MODEL OF SARS COV-2 IN YOUNG SYRIAN HAMSTERS FOR PRECLINICAL STUDIES. , 2022, , .		1
87	Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant. <i>PLoS Pathogens</i> , 2023, 19, e1011293.	4.7	7
88	Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses. <i>Annual Review of Animal Biosciences</i> , 2023, 11, 1-31.	7.4	8
89	SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum. <i>Viruses</i> , 2023, 15, 748.	3.3	1
90	Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. <i>Viruses</i> , 2023, 15, 914.	3.3	5
91	SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters. <i>MBio</i> , 0, , .	4.1	4
92	Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest. <i>Viruses</i> , 2023, 15, 1193.	3.3	2
93	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. <i>Communications Medicine</i> , 2023, 3, .	4.2	1
94	TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. <i>Cell</i> , 2023, 186, 3427-3442.e22.	28.9	31
96	Rehoming and Other Refinements and Replacement in Procedures Using Golden Hamsters in SARS-CoV-2 Vaccine Research. <i>Animals</i> , 2023, 13, 2616.	2.3	0

#	ARTICLE	IF	CITATIONS
97	Is there a correlation between antibiotic use and the severity or post-infection conditions of COVID-19 and other viral infections?. Clinical and Experimental Medicine, 0, , .	3.6	0
98	Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters. Frontiers in Immunology, 0, 14, .	4.8	3
99	Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon. Scientific Reports, 2023, 13, .	3.3	2
101	Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters. Viruses, 2024, 16, 122.	3.3	0
102	Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted. EBioMedicine, 2024, 100, 104960.	6.1	1